Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03927690
Recruitment Status : Recruiting
First Posted : April 25, 2019
Last Update Posted : March 16, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Tracking Information
First Submitted Date  ICMJE April 23, 2019
First Posted Date  ICMJE April 25, 2019
Last Update Posted Date March 16, 2020
Actual Study Start Date  ICMJE January 23, 2019
Estimated Primary Completion Date February 9, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 23, 2019)
  • Adverse event profile and safety endpoints of LKA651 [ Time Frame: Day 169 ]
    Incidence of treatment emergent adverse events and study drug related adverse events.
  • Effect of LKA651 on Best Corrected Visual Acuity (BCVA) [ Time Frame: Day 85 ]
    To determine Best Corrected Visual Acuity (BCVA) as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity charts
  • Effect of LKA651 on Central subfield retinal thickness [ Time Frame: Day 85 ]
    Change from baseline in Central subfield retinal thickness as measured by SD-OCT
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 23, 2019)
  • Evaluate the time to retreatment with anti-VEGF [ Time Frame: Day 169 ]
    To determine the time to retreatment with anti-VEGF (as determined by PI) after week 12
  • Cmax of LKA651 at steady state in patients with diabetic macular edema [ Time Frame: Day 169 ]
    To assess the Cmax of LKA651 at steady state in patients with diabetic macular edema
  • Cmax of ranizumab at steady state in patients with diabetic macular edema [ Time Frame: Day 169 ]
    To assess the Cmax of ranizumab at steady state in patients with diabetic macular edema
  • AUC0-28 of LKA651 at steady state in patients with diabetic macular edema [ Time Frame: Day 169 ]
    To assess the AUC0-28 of LKA651 at steady state in patients with diabetic macular edema
  • AUC0-28 of ranizumab at steady state in patients with diabetic macular edema [ Time Frame: Day 169 ]
    To assess the AUC0-28 of ranizumab at steady state in patients with diabetic macular edema
  • Effect of IVT LKA651 when administered alone or in combination with Lucentis® on DR progression in patients with DME [ Time Frame: Day 169 ]
    effect of IVT LKA651 when administered alone or in combination with Lucentis® on DR progression in patients with DME by improvement in the diabetic retinopathy severity scale by color fundus photos
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
Official Title  ICMJE A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema
Brief Summary To evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Diabetic Macular Edema
Intervention  ICMJE
  • Drug: LKA651
    LKA651 IVT
  • Drug: Lucentis
    Lucentis IVT
Study Arms  ICMJE
  • Experimental: LKA651
    LKA651 IVT
    Intervention: Drug: LKA651
  • Experimental: LKA651/Lucentis
    LKA651/Lucentis IVT
    Interventions:
    • Drug: LKA651
    • Drug: Lucentis
  • Active Comparator: Lucentis
    Lucentis IVT
    Intervention: Drug: Lucentis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 23, 2019)
90
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 9, 2021
Estimated Primary Completion Date February 9, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Written informed consent must be obtained before any assessment is performed.
  2. Male and female patients age 18 to 85 years of age inclusive at screening
  3. Presence of type I or type II diabetes mellitus
  4. The ETDRS letter score in the study eye must be between 24 and 70 letters (approximate Snellen equivalent of 20/40-20/320). The non-study eye (fellow eye) should be ≥34 letters or better (approximate Snellen equivalent of 20/200) at screening
  5. Presence of DME in the study eye, with decrease in vision due to foveal thickening of central macular thickness ≥ 320 µm in the central subfield, as assessed on SD-OCT and confirmed by the central reading center at screening

Other protocol specified inclusion/exclusion criteria apply.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Novartis Pharmaceuticals 1-888-669-6682 Novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111
Listed Location Countries  ICMJE Germany,   Puerto Rico,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03927690
Other Study ID Numbers  ICMJE CLKA651X2202
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Responsible Party Novartis ( Novartis Pharmaceuticals )
Study Sponsor  ICMJE Novartis Pharmaceuticals
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Novartis
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP